• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Making sense of antisense gene silencing

Bioengineer by Bioengineer
July 6, 2021
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Department of Neurology and Neurological Science,TMDU

Researchers from Tokyo Medical and Dental University (TMDU) find proteins that bind to and regulate tocopherol-conjugated heteroduplex oligonucleotides during gene silencing

Tokyo, Japan – Gene silencing therapies are used to interfere with, or “silence”, the expression of genes that are associated with disorders. Now, a team at TMDU has uncovered some of the cellular mechanisms by which the silencing therapies act in cells.

Antisense oligonucleotide (ASO) therapies use small strands of DNA or RNA that are antisense, or complementary, to the associated gene to interfere with its expression. ASO therapies are already available for some diseases, particularly neurological disorders, but their use is at a very early stage. It is known that modifying ASOs chemically can improve the efficacy of the therapy. The team at TMDU had previously achieved gene silencing by attaching alpha-tocopherol (Toc) to ASOs. They then created Toc-HDOs by attaching Toc to DNA/RNA heteroduplex oligonucleotides, which are double-stranded molecules consisting of one strand of DNA and one strand of RNA. Toc-HDOs are more potent, stable, and efficiently taken up by target tissues than ASOs, and so have great therapeutic potential.

However, very little is known about the mechanism by which Toc-HDOs function. ASOs are known to interact with proteins at every step of the gene silencing process, but none have been identified for Toc-HDOs. The team also wanted to investigate the possibility that the therapeutic effects of Toc-HDO might occur through a different mechanism to other ASOs, leading to the increased potency.

In this latest study, the researchers identified four proteins, annexin A5 (ANXA5), carbonic anhydrase 8 (CA8), apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1), and flap structure-specific endonuclease 1 (FEN1), all of which bind to Toc-HDO. “We injected mice with fluorescently-labelled Toc-HDOs to identify potential binding proteins,” says lead author Ken Asada. “We then characterised the proteins further and showed that they are able to directly bind with Toc-HDOs in vitro.”

The team demonstrated that these four proteins control the function of Toc-HDO and may bind together to form a complex to regulate gene silencing. “Tocopherol enhanced the binding activity of these proteins,” says Takanori Yokota, senior author, “so this mechanism is a possible reason for the greater therapeutic potential shown by Toc-HDOs.”

In this work, the researchers uncovered a novel biological mechanism, increasing understanding of how Toc-HDOs work to silence genes. This will allow the development of improved gene silencing therapies that are more potent and less toxic, advancing the field significantly.

###

The paper “Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing” was published in Nucleic Acids Research at DOI: 10.1093/nar/gkab258

Media Contact
Takanori Yokota
[email protected]

Original Source

https://www.tmd.ac.jp/english/press-release/20210430-1/

Related Journal Article

http://dx.doi.org/10.1093/nar/gkab258

Tags: BiochemistryGene TherapyMedicine/HealthMolecular Biology
Share12Tweet8Share2ShareShareShare2

Related Posts

How Role Identity Affects Nurse Practitioners’ Cultural Competence

September 7, 2025

Parental KMO Genotype Influences Offspring Behavior Differently by Sex

September 7, 2025

Systemic Immune-Inflammation Index Predicts Heart Failure Risks

September 7, 2025

5-T MRI Reveals Brain’s Perivascular Spaces

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    46 shares
    Share 18 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

How Role Identity Affects Nurse Practitioners’ Cultural Competence

Parental KMO Genotype Influences Offspring Behavior Differently by Sex

Systemic Immune-Inflammation Index Predicts Heart Failure Risks

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.